CD26 inhibition enhances perfusion recovery in ApoE-/-mice

Current Vascular Pharmacology

Volumn 11, Issue 1, 2013, Pages 21-28

  Haverslag, René T ^a   de Groot, Daphne ^a   Grundmann, Sebastian ^b   Meder, Benjamin ^c   Goumans, Marie José ^d   Pasterkamp, Gerard ^a   Hoefer, Imo E ^a   de Kleijn, Dominique P V ^a,e  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

Author keywords

CD26; Collateral circulation; Leukocytes; Perfusion recovery; SDF 1 alpha

Indexed keywords

APOLIPOPROTEIN E; CHEMOKINE RECEPTOR CXCR; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; PLACEBO; STROMAL CELL DERIVED FACTOR 1ALPHA;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTERY OCCLUSION; ARTICLE; ATHEROSCLEROSIS; CELL INFILTRATION; CELL MIGRATION; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRAVASATION; FEMORAL ARTERY; FLOW CYTOMETRY; HEMODYNAMIC PARAMETERS; IMMUNOHISTOCHEMISTRY; MONOCYTE; MOUSE; NONHUMAN; PERFUSION;

EID: 84873167883     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016113804547566     Document Type: Article

References (33)

1. Heil M, Schaper W. Influence of mechanical, cellular, and molecular factors on collateral artery growth (arteriogenesis). Circ Res 2004; 95: 449-58.
2. Schaper W. Collateral circulation: past and present. Basic Res Cardiol 2009; 104: 5-21.
3. Schirmer SH, van Nooijen FC, Piek JJ, van RN. Stimulation of collateral artery growth: travelling further down the road to clinical application. Heart 2009; 95: 191-7.
4. Scholz D, Ito W, Fleming I, et al. Ultrastructure and molecular histology of rabbit hind-limb collateral artery growth (arteriogenesis). Virchows Arch 2000; 436: 257-70.
5. Grundmann S, Piek JJ, Pasterkamp G, Hoefer IE. Arteriogenesis: basic mechanisms and therapeutic stimulation. Eur J Clin Invest 2007; 37: 755-66.
6. Epstein SE, Stabile E, Kinnaird T, et al. Janus phenomenon: the interrelated tradeoffs inherent in therapies designed to enhance collateral formation and those designed to inhibit atherogenesis. Circulation 2004; 109: 2826-31.
7. van Royen N, Hoefer I, Bottinger M, et al. Local monocyte chemoattractant protein-1 therapy increases collateral artery formation in apolipoprotein E-deficient mice but induces systemic monocytic CD11b expression, neointimal formation, and plaque progression. Circ Res 2003; 92: 218-25.
8. Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, Springer TA. A highly efficacious lymphocyte chemoattractant, stromal cellderived factor 1 (SDF-1). J Exp Med 1996; 184: 1101-9.
9. Bleul CC, Farzan M, Choe H, et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996; 382: 829-33.
10. De Falco E, Porcelli D, Torella AR, et al. SDF-1 involvement in endothelial phenotype and ischemia-induced recruitment of bone marrow progenitor cells. Blood 2004; 104: 3472-82.
11. Peled A, Kollet O, Ponomaryov T, et al. The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34(+) cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice. Blood 2000; 95: 3289-96.
12. Proost P, Struyf S, Schols D, et al. Processing by CD26/dipeptidylpeptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1alpha. FEBS Lett 1998; 432: 73-6.
13. Herman GA, Stevens C, Van DK, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005; 78: 675-88.
14. Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006; 49: 2564-71.
15. Post S, Smits AM, van den Broek AJ, et al. Impaired recruitment of HHT-1 mononuclear cells to the ischaemic heart is due to an altered CXCR4/CD26 balance. Cardiovasc Res 2010; 85: 494-502.
16. Ye Y, Keyes KT, Zhang C, et al. The myocardial infarct sizelimiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. Am J Physiol Heart Circ Physiol 2010; 298: H1454-H1465.
17. Zaruba MM, Theiss HD, Vallaster M, et al. Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. Cell Stem Cell 2009; 4: 313-23.
18. Hoefer IE, van RN, Rectenwald JE, et al. Direct evidence for tumor necrosis factor-alpha signaling in arteriogenesis. Circulation 2002; 105: 1639-41.
19. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg 2007; 33 (Suppl 1): S1-75.
20. Lambeir AM, Durinx C, Scharpe S, De MI. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003; 40: 209-94.
21. Heil M, Ziegelhoeffer T, Pipp F, et al. Blood monocyte concentration is critical for enhancement of collateral artery growth. Am J Physiol Heart Circ Physiol 2002; 283: H2411-H2419.
22. Christopherson KW, Hangoc G, Mantel CR, Broxmeyer HE. Modulation of hematopoietic stem cell homing and engraftment by CD26. Science 2004; 305: 1000-3.
23. Salmi M, Jalkanen S. Cell-surface enzymes in control of leukocyte trafficking. Nat Rev Immunol 2005; 5: 760-71.
24. Ley K. Arrest chemokines. Microcirculation 2003; 10: 289-95.
25. Ganju RK, Brubaker SA, Meyer J, et al. The alpha-chemokine, stromal cell-derived factor-1alpha, binds to the transmembrane Gprotein-coupled CXCR-4 receptor and activates multiple signal transduction pathways. J Biol Chem 1998; 273: 23169-75.
26. de Groot D, Haverslag RT, Pasterkamp G, de Kleijn DP, Hoefer IE. Targeted deletion of the inhibitory NF-{kappa}B p50 subunit in bone marrow-derived cells improves collateral growth after arterial occlusion. Cardiovasc Res 2010; 88: 179-85.
27. Sakihama H, Masunaga T, Yamashita K, et al. Stromal cell-derived factor-1 and CXCR4 interaction is critical for development of transplant arteriosclerosis. Circulation 2004; 110: 2924-30.
28. Zernecke A, Schober A, Bot I, et al. SDF-1alpha/CXCR4 axis is instrumental in neointimal hyperplasia and recruitment of smooth muscle progenitor cells. Circ Res 2005; 96: 784-91.
29. Ghitescu L, Robert M. Diversity in unity: the biochemical composition of the endothelial cell surface varies between the vascular beds. Microsc Res Tech 2002; 57: 381-9.
30. Ebnet K, Vestweber D. Molecular mechanisms that control leukocyte extravasation: the selectins and the chemokines. Histochem Cell Biol 1999; 112: 1-23.
31. Zernecke A, Bot I, Djalali-Talab Y, et al. Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ Res 2008; 102: 209-17.
32. Damas JK, Waehre T, Yndestad A, et al. Stromal cell-derived factor-1alpha in unstable angina: potential antiinflammatory and matrix-stabilizing effects. Circulation 2002; 106: 36-42.
33. Hosono M, de Boer OJ, van der Wal AC, et al. Increased expression of T cell activation markers (CD25, CD26, CD40L and CD69) in atherectomy specimens of patients with unstable angina and acute myocardial infarction. Atherosclerosis 2003; 168: 73-80.